H.C. Wainwright raised the firm’s price target on Lifeward to $9 from $3 and keeps a Buy rating on the shares after the company announced that Centers for Medicare & Medicaid Services finalized the reimbursement fee schedule for the ReWalk Exoskeleton, with a price range of $81,929-$109,238. The firm believes CMS finalizing the reimbursement amount and allowing it to be retroactive from April 1,could potentially trigger some pent-up demand and drive adoption of the ReWalk Exoskeleton.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFWD:
- Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton
- CMS revises 2024 fee schedule to include ReWalk Personal Exoskeleton rate
- Rewalk Robotics Clarifies Regulatory Disclosure Standards
- Lifeward CEO updates shareholders on Exoskeleton and Medicare progress
- Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate
